Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Recent Progression and Perspective
- 1 February 2013
- journal article
- Published by S. Karger AG in Oncology
- Vol. 84 (Suppl. 1) , 28-33
Abstract
Transcatheter arterial chemoembolization (TACE) is widely performed in 32% of patients with unresectable hepatocellular carcinoma (HCC) at initial diagnosis and in 58% of those with recurrent HCC in Japan. However, the patient population which undergoes TACE is heterogeneous, and thus the 3-year survival rate varies from 26 to 47%. The selection criteria for TACE is 2-3 tumors >3 cm or 4 or more tumors in patients with liver damage A/B (corresponding well to Child-Pugh class A/B) and absence of vascular invasion and extrahepatic spread, as proposed by Japanese guidelines. The 3-year survival rate of TACE for patients with 2-3 tumors >3 cm or 4 or more tumors was 55 and 46%, respectively, in Child-Pugh A and 30 and 22%, respectively, in class B. These outcomes could help in understanding the various results of TACE in different backgrounds in the East and West. Recently, TACE with calibrated drug-eluting beads loaded with doxorubicin showed a similar tumor response and radioembolization with yttrium-90 microspheres demonstrated a similar median survival compared with conventional TACE. Based on these results, the combination of TACE and novel molecular targeted agents can be used to elucidate the synergic effect on survival.Keywords
This publication has 46 references indexed in Scilit:
- Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted TherapyLiver Cancer, 2012
- Chemoembolization in Patients with Hepatocellular CarcinomaLiver Cancer, 2012
- Report of the 18th follow‐up survey of primary liver cancer in JapanHepatology Research, 2010
- Design and Endpoints of Clinical Trials in Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2008
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Hepatocellular carcinoma in cirrhosis: Incidence and risk factorsGastroenterology, 2004
- Hepatocellular carcinoma: Recent trends in the United StatesGastroenterology, 2004
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002